Vialwirebiotech, curated
July 3, 2026, 5:22 PM
May 20, 2026
- 2:48 PM · STAT News
- 2:12 PM · Endpoints News2:12 PMI&I biotech cAMPfield attracts top-tier investors in $180M Series A — Endpoints News
- 12:00 PM · BioWorld12:00 PMFDA approval advances personalized cancer diagnostics — BioWorld
- 12:00 PM · BioWorld12:00 PMImmunovant rises on IMVT-1402 data in difficult-to-treat RA — BioWorld
- 9:49 AM · Drug Discovery World9:49 AMCyclana Bio gets green light to launch endometriosis trial — Drug Discovery World
- 9:00 AM · BioWorld9:00 AMMatter Bio files IND for Lm-LLO-TT for PDAC — BioWorld
- 9:00 AM · BioWorld9:00 AMRe-Aim Therapeutics launches with focus on autoimmune diseases — BioWorld
- 9:00 AM · BioWorld9:00 AMDropshot advances renal target under Etherna collaboration — BioWorld
- 9:00 AM · BioWorld9:00 AMMekanistic’s PI3K/EGFR inhibitor MTX-531 gains IND clearance — BioWorld
- 7:40 AM · Science (News)7:40 AMNot alive, but not dead: disembodied human brains used for drug testing — Science (News)
- 6:15 AM · Pharmaceutical Technology6:15 AMTakeda faces $885m hit after landmark pay-for-delay lawsuit verdict — Pharmaceutical Technology
- 6:00 AM · Pharmaceutical Executive6:00 AM<![CDATA[Positioning TGN-S15 as Synergistic With Keytruda in HPV-Induced Cancers]]> — Pharmaceutical Executive
- 5:42 AM · Drug Discovery World5:42 AMMestag doses first patient in treatment for solid tumours — Drug Discovery World
- 5:22 AM · Pharmaceutical Technology5:22 AMQIAGEN and NVIDIA partner on AI drug discovery — Pharmaceutical Technology
- 4:52 AM · Pharmaceutical Technology4:52 AMSERB signs agreement to acquire Idefirix rights for $133.6m — Pharmaceutical Technology
- 3:55 AM · BioPharma Dive3:55 AMLilly snaps up Engage to advance non-viral genetic medicines — BioPharma Dive
- 12:00 AM · FT — Pharmaceuticals12:00 AMBig Europe and Asian private equity health funds merge to defy AI disruption — FT — Pharmaceuticals
May 19, 2026
- 9:35 PM · STAT News9:35 PMSTAT+: 23andMe offers to connect users’ DNA data with medical records — STAT News
- 2:56 PM · Endpoints News2:56 PMAnother Paragon offshoot chooses reverse merger, this time for migraine drugs — Endpoints News
- 2:15 PM · Endpoints News2:15 PMAcceleron leaders and Westlake jumpstart new IPF biotech — Endpoints News
- 1:05 PM · The Guardian — Science1:05 PMArtificial eggshell comes first in attempt to revive giant flightless moa — The Guardian — Science
- 12:00 PM · BioWorld12:00 PMDegron closes $40M series A to advance molecular glue degraders — BioWorld
- 12:00 PM · BioWorld12:00 PMFosun secures rights to Aribio’s AR-1001 in potential $4.7B deal — BioWorld
- 12:00 PM · BioWorld12:00 PMDaewoong nabs Innovo’s preclinical IBD asset in ₩663B deal — BioWorld
- 12:00 PM · BioWorld12:00 PMVincentage’s oral GLP-1 meets phase III obesity endpoints — BioWorld
- 12:00 PM · BioWorld12:00 PMCreate Medicines secures $122M for in vivo CARs — BioWorld
- 11:22 AM · Endpoints News11:22 AMQ&A: Novo research chief Petersen says streamlined R&D speeds discovery — Endpoints News
- 11:19 AM · Endpoints News11:19 AMWave aims for monthly dosing with RNA editing treatment for AATD — Endpoints News
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMBiocryst’s BCX-17725 as new approach for Netherton syndrome — BioWorld
- 9:00 AM · BioWorld9:00 AMKorro Bio nominates new candidate for AATD — BioWorld
- 9:00 AM · BioWorld9:00 AMChina’s NMPA clears KAT6 inhibitor SYH-2095 for clinic — BioWorld
- 9:00 AM · BioWorld9:00 AMIksuda and UCL report new B7-H3-targeting ADCs — BioWorld
- 8:56 AM · Drug Discovery World8:56 AMOutSee receives Discovery Award from Longitude Prize on ALS — Drug Discovery World
- 7:13 AM · Endpoints News7:13 AMRelay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study — Endpoints News
- 6:18 AM · Endpoints News6:18 AMBioMarin's rare disease therapy shows no clinical benefit in Phase 3 test — Endpoints News
- 5:45 AM · Pharmaceutical Technology5:45 AMVERTANICAL’s VER-01 gains FDA breakthrough status for low back pain — Pharmaceutical Technology
- 5:16 AM · Pharmaceutical Technology5:16 AMRegeneron signs $2.32bn deal with Parabilis for Helicon conjugates — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMNew Fact Sheet: Liver organoid platform for predictive hepatotoxicity assessment — Drug Discovery World
May 18, 2026
- 6:08 PM · STAT News6:08 PMSTAT+: Maryland state affordability board places a price cap on Ozempic — STAT News
- 5:29 PM · TechCrunch